IDEXX LABORATORIES INC /DE News
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
see moreIDEXX LABORATORIES INC /DE Market News
6d
IDEXX Laboratories Enhances Veterinary Diagnostics with Integrated SDMA Testing
- IDEXX integrates SDMA into Catalyst CLIPs, advancing kidney diagnostics.
13d
IDEXX Laboratories Enhances Diagnostic Capabilities with Taeniid Tapeworm Detection
IDEXX expands Fecal Dx™ platform to detect taeniid tapeworms in pets.
19d
IDEXX Laboratories Reports Strong Q1 2026 Results, Boosts Annual Outlook
IDEXX Laboratories posts 14% revenue growth in Q1 2026, raises annual guidance.
27 Feb at 10:11
IDEXX Q4 Beat & New AI Radiography Fuel Growth Now
IDEXX delivered a Q4 beat with stronger revenue, EPS and placements while launching AI-enhanced ImageVue DR50 Plus and expanding cancer diagnostics—moves that reinforce recurring revenue but triggered only a muted stock response.
20 Feb at 10:12
IDEXX Q4 Beat: Record Placements, Strong 2026 Path
IDEXX posted a Q4 double beat with $1.09B revenue, record inVue Dx placements, and raised 2026 guidance—yet the stock reaction was muted. Strength across consumables, instruments, software, water and livestock testing underpins a durable recurring-revenue model and longer-term analyst upside.
13 Feb at 10:12
IDEXX Unveils DR50 Plus, Cancer Dx; Erickson CEO!!
IDEXX announced the ImageVue DR50 Plus radiography system, expanded its Cancer Dx panel to detect canine mast cell tumors, and named Michael Erickson as CEO effective May 12, 2026—developments that strengthen product-led revenue streams and governance continuity for IDXX investors.
06 Feb at 10:13
IDEXX Q4 Beat, Guidance Up; Vet Visits Cloud Rally!
IDEXX reported a stronger-than-expected Q4 with robust instrument placements and raised 2026 guidance, yet shares dipped as investors digested softer veterinary visit trends. Diagnostics, software adoption and new in-clinic instruments underpin growth, while water and livestock testing remain strategic but unchanged this week.